Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1

被引：0

作者：

Gupta, Vikas ^{[1
]}

Oh, Stephen ^{[2
]}

Devos, Timothy ^{[3
,4
]}

Dubruille, Viviane ^{[5
]}

Catalano, John ^{[6
,7
]}

Somervaille, Timothy ^{[8
,9
]}

Giraldo, Pilar ^{[10
,11
]}

Kosugi, Hiroshi ^{[12
]}

Sacha, Tomasz ^{[13
]}

Mayer, Jiri ^{[14
]}

Illes, Arpad ^{[15
]}

Ellis, Catherine ^{[16
]}

Wang, Zhaohui ^{[16
]}

Kawashima, Jun ^{[17
]}

Mesa, Ruben ^{[18
]}

机构：

[1] Princess Margaret Canc Ctr, Toronto, ON, Canada

[2] Washington Univ, Sch Med, St Louis, MO 14263 USA

[3] Univ Hosp Leuven, Leuven, Belgium

[4] Katholieke Univ Leuven, Leuven, Belgium

[5] CHU Nantes, Nantes, France

[6] Monash Univ, Frankston, Australia

[7] Frankston Hosp, Frankston, Australia

[8] Christie NHS Fdn Trust, Manchester, Lancs, England

[9] Canc Res UK Manchester Inst, Manchester, Lancs, England

[10] Miguel Servet Univ Hosp, Zaragoza, Spain

[11] Ctr Invest Biomed Red Enfermadades Raras, Zaragoza, Spain

[12] Ogaki Municipal Hosp, Ogaki, Japan

[13] Jagiellonian Univ Hosp, Krakow, Poland

[14] Univ Hosp Brno, Brno, Czech Republic

[15] Univ Debrecen, Dept Internal Med, Div Haematol, Fac Med, Debrecen, Hungary

[16] GSK Plc, Philadelphia, PA USA

[17] Sierra Oncol, San Mateo, CA USA

[18] Wake Forest Univ, Sch Med, Winston Salem, NC USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

MPN; myelofibrosis; momelotinib; anemia; hemoglobin;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MPN-551

引用

页码：S402 / S403

页数：2

共 31 条

[1] Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial
Gupta, Vikas
Oh, Stephen
Devos, Timothy
Dubruille, Viviane
Catalano, John
Somervaille, Tim C. P.
Platzbecker, Uwe
Giraldo, Pilar
Kosugi, Hiroshi
Sacha, Tomasz
Mayer, Jiri
Illes, Arpad
Ellis, Catherine
Wang, Zhaohui
Gonzalez Carreras, Francisco J.
Strouse, Bryan
Mesa, Ruben
LEUKEMIA & LYMPHOMA, 2024, 65 (07) : 965 - 977
[2] Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial
Gupta, Vikas
Oh, Stephen
Devos, Timothy
Dubruille, Viviane
Catalano, John
Somervaille, Tim C. P.
Platzbecker, Uwe
Giraldo, Pilar
Kosugi, Hiroshi
Sacha, Tomasz
Mayer, Jiri
Illes, Arpad
Ellis, Catherine
Wang, Zhaohui
Gonzalez Carreras, Francisco J.
Strouse, Bryan
Mesa, Ruben
LEUKEMIA & LYMPHOMA, 2024, 65 (07) : 965 - 977
[3] Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2
Harrison, Claire N.
Vannucchi, Alessandro M.
Recher, Christian
Passamonti, Francesco
Gerds, Aaron T.
Hernandez-Boluda, Juan Carlos
Yacoub, Abdulraheem
Sirhan, Shireen
Ellis, Catherine
Patel, Bharat
Strouse, Bryan
Platzbecker, Uwe
ADVANCES IN THERAPY, 2024, 41 (09) : 3722 - 3735
[4] Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial
Shimoda, Kazuya
Komatsu, Norio
Matsumura, Itaru
Ikeda, Kazuhiko
Hino, Masayuki
Hidaka, Michihiro
Maeda, Yoshinobu
Kondo, Takeshi
Fujisaki, Tomoaki
Shoshi, Keita
Azuma, Kyoichi
Fukushima, Ryuichi
Kawashima, Jun
Kosugi, Hiroshi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (03) : 314 - 324
[5] Indirect Treatment Comparisons of Momelotinib vs Pacritinib Safety and Anemia Outcomes in Patients With Myelofibrosis
Masarova, Lucia
Verstovsek, Srdan
Palandri, Francesca
Mesa, Ruben
Harrison, Claire
Dobi, Balazs
Gorsh, Boris
Wang, Zhaohui
Ellis, Catherine
Patnaik, Dwaipayan
Kapetanakis, Venediktos
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S381 - S382
[6] Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
Mesa, Ruben
Harrison, Claire
Oh, Stephen T.
Gerds, Aaron T.
Gupta, Vikas
Catalano, John
Cervantes, Francisco
Devos, Timothy
Hus, Marek
Kiladjian, Jean-Jacques
Lech-Maranda, Ewa
McLornan, Donal
Vannucchi, Alessandro M.
Platzbecker, Uwe
Huang, Mei
Strouse, Bryan
Klencke, Barbara
Verstovsek, Srdan
LEUKEMIA, 2022, 36 (09) : 2261 - 2268
[7] Transfusion-Related Cost and Time Burden Offsets in Patients with Myelofibrosis Treated with Momelotinib in the SIMPLIFY-1 and SIMPLIFY-2 Trials
Masarova, Lucia
Liu, Tom
Fillbrunn, Mirko
Li, Weilong
Sajeev, Gautam
Rao, Sumati
Gorsh, Boris
Signorovitch, James
CANCERS, 2024, 16 (23)
[8] Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients
Mesa, Ruben
Hudgens, Stacie
Floden, Lysbeth
Palmer, Jeanne
Gupta, Vikas
McLornan, Donal
McMullin, Mary Frances
Kiladjian, Jean-Jacques
Foltz, Lynda
Platzbecker, Uwe
Fox, Maria Laura
Mead, Adam
Ross, David
Oh, Stephen
Perkins, Andrew
Leahy, Michael
Deheshi, Samineh
Donahue, Rafe
Klencke, Barbara
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S360 - S360
[9] Transfusion Intensity Over Time in Patients From the Phase 3 SIMPLIFY-1 and MOMENTUM Trials of Momelotinib
Mesa, Ruben
Perkins, Andrew
Goh, Yeow Tee
Fox, Maria Laura
McLornan, Donal
Palmer, Jeanne
Foltz, Lynda
Vannucchi, Alessandro
Koschmieder, Steffen
Passamonti, Francesco
Lee, Sung Eun
Kawashima, Jun
Strouse, Bryan
Carreras, Francisco Gonzalez
Oh, Stephen
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S411 - S411
[10] Impact of Transfusion Burden on Health-Related Quality of Life and Functioning in Patients With Myelofibrosis: Post Hoc Analysis of SIMPLIFY-1 and-2
Mesa, Ruben
Palandri, Francesca
Verstovsek, Srdan
Masarova, Lucia
Harrison, Claire
Mazerolle, Flora
Gorsh, Boris
M'hari, Manal
Wang, Zhaohui
Ellis, Catherine
Deheshi, Samineh
Kawashima, Jun
von Maltzahn, Robyn
Regnault, Antoine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S382 - S382

← 1 2 3 4 →